Filed on behalf of: Sawai USA, Inc. and Sawai Pharmaceutical Co., Ltd.
By: Brian J. Sodikoff
Martin S. Masar III
KATTEN MUCHIN ROSENMAN, LLP
525 W. Monroe St.
Chicago, IL 60661
Tel.: 312-902-5200
Fax: 312-902-1061
Email: brian.sodikoff@kattenlaw.com
Email: martin.masar@kattenlaw.com

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAWAI USA, INC. and SAWAI PHARMACEUTICAL CO., LTD.,
Petitioners,

v.

ASTELLAS PHARMA INC.,
Patent Owner

Case No. IPR__
Patent No. 6,346,532

PETITION FOR INTER PARTES REVIEW

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

TABLE OF CONTENTS

Page

I. INTRODUCTION 1

A. Brief Overview of the Challenged Claims. 1

1. "Compound" claims 1, 3-6, 9, and 15 all include mirabegron. 2

2. "Composition" claims 11, 12, and 16 all include mirabegron formulated with pharmaceutically acceptable carriers. 4

B. Brief Overview of the Relevant Technology. 4

II. STATEMENT OF PRECISE RELIEF FOR EACH CLAIM CHALLENGED 10

III. CLAIM CONSTRUCTION 11

IV. LEVEL OF ORDINARY SKILL IN THE ART 11

V. DETAILED EXPLANATION OF GROUNDS FOR UNPATENTABILITY 14

A. [Ground 1] Claims 1, 3-6, 9, 11, 12, 15, and 16 were Obvious Under 35 U.S.C. § 103 Over Merck US197, in view of Blin, in Combination with Silverman and/or Thornber. 14

1. Under the Proper Legal Framework, the Obviousness Analysis Starts with the Most Structurally Similar Compound in the Prior Art. 14

2. Because Mirabegron was Obvious, Each of the Challenged Claims are Unpatentable. 18

3. "Compound" Claims 1, 3-6, 9, and 15 were Obvious Because a POSA Would Have Been Motivated to Make Mirabegron with a Reasonable Expectation of Success. 19

a. Merck US197 Disclosed Mirabegron Sulfonamide and its Utility as a β3-Agonist. 21

DOCKET ALARM

Find authenticated court documents without watermarks at docketalarm.com.

b. A POSA Would Have Been Motivated to Change the Sulfonamide into an Amide with a Reasonable Expectation of Success in Making Mirabegron and It Being a Selective β3-Agonist. 26

4. "Composition" Claims 11, 12, and 16 Were Obvious Because a POSA Would Have Been Motivated to Make a Composition Comprising Mirabegron and a Pharmaceutical Carrier with a Reasonable Expectation of Success. 31

5. Conclusion of Ground 1. 33

B. [Ground 2] Claims 1, 3-6, 9, 11, 12, 15, and 16 Were Obvious Under 35 U.S.C. § 103 Over Merck US197, in view of Blin, in Combination with Merck US048 and Silverman and/or Thornber. 36

1. "Compound" Claims 1, 3-6, 9, and 15 were Obvious Because a POSA Would Have Been Motivated to Make Mirabegron with a Reasonable Expectation of Success. 37

a. A POSA Would Have Selected the Merck US197 Table 3 Compounds as Lead Compounds. 37

b. A POSA Would Have Been Motivated to Modify the Merck US197 Lead Compounds to Make Mirabegron With a Reasonable Expectation of Success. 42

2. "Composition" Claims 11, 12, and 16 Were Obvious Because a POSA Would Have Been Motivated to Make a Composition Comprising Mirabegron and a Pharmaceutical Carrier with a Reasonable Expectation of Success. 48

3. Conclusion of Ground 2. 48

C. Secondary Considerations 52

VI. GROUNDS FOR STANDING 54

VII. MANDATORY NOTICES UNDER 37 C.F.R. § 42.8 55

DOCKET ALARM

Find authenticated court documents without watermarks at docketalarm.com.

VIII. PAYMENT OF FEES UNDER 37 C.F.R. §§ 42.15(A) AND 42.103 56

IX. CONCLUSION 56

X. APPENDIX – LIST OF EXHIBITS.....1

DOCKET ALARM

Find authenticated court documents without watermarks at docketalarm.com.

TABLE OF AUTHORITIES

Page(s)

Cases

In re Albrecht,
514 F.2d 1385 (C.C.P.A. 1975).....14

Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc.,
752 F.3d 967 (Fed. Cir. 2014).....54

Ex parte Cao,
No. 2010-00408 (B.P.A.I. Sept. 21, 2011) 17

In re Cuozzo Speed Techs., LLC,
778 F.3d 1271 (Fed. Cir. 2015).....11

Daiichi Sankyo Co. v. Matrix Labs., Ltd.,
619 F.3d 1346 (Fed. Cir. 2010).....36

In re Dillon,
919 F.2d 688 (Fed. Cir. 1990) (en banc) .....passim

Ex parte Dong,
No. 2011-010047 (P.T.A.B. Jan. 28, 2013).....18

EWP Corp. v. Reliance Universal Inc.,
755 F.2d 898 (Fed. Cir. 1985).....15

In re Fulton,
391 F.3d 1195 (Fed. Cir. 2004).....17

Ex parte Gaul,
No. 2011-008222 (B.P.A.I. Jan. 5, 2012).....18

In re Grabiak,
769 F.2d 729 (Fed. Cir. 1985).....18

Graham v. John Deere Co.,
383 U.S. 1 (1966).....16

In re Grasselli,
713 F.2d 731 (Fed. Cir. 1983).....53

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.